Welcome to our dedicated page for Lisata Therapeutics news (Ticker: LSTA), a resource for investors and traders seeking the latest updates and insights on Lisata Therapeutics stock.
Overview
Lisata Therapeutics Inc (LSTA) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies designed to treat advanced solid tumors and other significant diseases. Leveraging cutting-edge peptide technology, the company is focused on addressing major unmet medical needs in oncology by enhancing the delivery of anti-cancer drugs through a novel uptake pathway. Keywords such as clinical-stage pharmaceutical, solid tumors, and oncology are essential in understanding the company's core focus.
Innovative Technologies and Product Pipeline
At the heart of Lisata Therapeutics' robust research and development efforts is its investigational product, certepetide. This cyclic iRGD peptide is engineered to activate a unique uptake pathway, enabling co-administered or tethered anti-cancer drugs to selectively penetrate and accumulate within solid tumors. By effectively modifying the tumor microenvironment and reducing its immunosuppressive characteristics, certepetide offers an advanced method to enhance the efficacy of conventional chemotherapy, immunotherapies, and RNA-based therapeutics.
The company employs its proprietary CendR Platform technology as a foundation for its research, supporting multiple clinical trials across various tumor types. With studies evaluating the safety, tolerability, and therapeutic potential of certepetide in combination with standard-of-care regimens, Lisata is actively exploring opportunities in both first-line and second-line therapeutic settings. This strategic approach facilitates a comprehensive evaluation of the product across a range of cancers, including pancreatic, cholangiocarcinoma, glioblastoma, colon, and melanoma.
Research & Development and Strategic Collaborations
Lisata Therapeutics stands out for its commitment to extensive research and collaboration. The company has established noteworthy partnerships with academic institutions, biotechnology firms, and diagnostic innovators to accelerate the clinical development of its product candidates. These collaborations not only reflect the company’s expertise in translational medicine but also support the integration of novel diagnostic strategies, such as advanced imaging and molecular assays, to monitor therapeutic response accurately.
Through its diversified clinical trial portfolio, Lisata is engaged in both early and pivotal phase studies, evaluating the role of certepetide in enhancing drug delivery and achieving better patient outcomes. The company’s strategic initiatives have been structured to address the challenges inherent in targeting advanced solid tumors and to provide detailed insights into the mechanism of drug-tumor interactions.
Market Position and Significance
Within the competitive landscape of oncology therapeutics, Lisata Therapeutics is recognized for its innovative approach to drug delivery and tumor targeting. The company's scientific strategy, rooted in the modification of the tumor microenvironment and enhanced drug penetration, offers substantial differentiation from other therapeutic modalities. This focus on leveraging peptide technology to improve the performance of co-administered anti-cancer agents positions Lisata as an important contributor to the evolving cancer treatment paradigm.
Lisata’s comprehensive approach—spanning drug development, strategic partnerships, and collaborative research—underscores its commitment to advancing treatment options for patients with difficult-to-treat malignancies. The scientific rigor applied in its clinical studies and the transparent dissemination of clinical milestones underscore the company’s dedication to improving our understanding of tumor biology and therapeutic innovation.
Clinical Trials and Future Directions
While Lisata is known for its robust pipeline and forward-thinking clinical programs, the company remains focused on providing critical data from its ongoing investigations. The breadth of its trial portfolio not only includes evaluations in solid tumor oncology but also extends into exploring non-oncology applications, reflecting the versatility of its technology platform. Each study is designed to yield actionable insights regarding therapeutic activity and safety, thereby reinforcing the scientific competence and credibility of the company.
In summary, Lisata Therapeutics exemplifies a modern biopharmaceutical company that combines advanced peptide technology with a strategic, research-driven approach to address some of the most challenging therapeutic needs in oncology today. Its comprehensive and methodical R&D efforts, bolstered by strategic collaborations and a clear focus on enhancing drug delivery, make it a significant entity within the field of targeted cancer therapies.
Lisata Therapeutics, a clinical-stage pharmaceutical company focused on therapies for advanced solid tumors and other serious diseases, announced that its President and CEO, David J. Mazzo, Ph.D., will present at the Investival Showcase USA. The event is scheduled for March 10-11, 2025, in Miami, Florida.
Dr. Mazzo's presentation will occur on March 11th at 11:30 a.m. Eastern Time. For more information about the conference and registration details, please click here.
Lisata Therapeutics (NASDAQ: LSTA) and GATC Health have initiated a strategic collaboration leveraging GATC's AI-powered Multiomics Advanced Technology™ (MAT) platform to optimize and accelerate drug development. The partnership's first phase will analyze Lisata's investigational drug certepetide, focusing on optimizing its Phase 3 development for metastatic pancreatic ductal adenocarcinoma (mPDAC) and identifying new potential indications.
The collaboration will proceed in multiple steps: First, analyzing certepetide's potential applications; second, identifying potential drug combinations across various indications; and finally, establishing Lisata as GATC's operational partner for developing GATC's drug candidates. GATC's MAT AI platform simulates billions of biological interactions to predict safety, efficacy, and clinical trial outcomes.
This partnership aims to address traditional drug development challenges, including high failure rates (1 in 10,000 drugs reach market) and lengthy development timelines, by enabling more focused studies and optimized capital management through AI-driven analysis.
Lisata Therapeutics (NASDAQ: LSTA) has reported its full year 2024 financial results and provided updates on its development portfolio. The company's primary focus is on certepetide, a novel treatment for advanced solid tumors. Key highlights include promising preliminary Phase 2b (ASCEND) pancreatic cancer data from Cohort A, with Cohort B data expected in coming months.
Financial results show revenue of $1.0 million from a Kuva Labs licensing agreement, while operating expenses decreased 8.9% to $23.4 million. Net losses were $20.0 million for 2024, compared to $20.8 million in 2023. The company maintains a strong financial position with $31.2 million in cash and equivalents, providing runway into Q2 2026.
Multiple clinical trials are advancing, including ASCEND, BOLSTER, CENDIFOX, and iLSTA, evaluating certepetide across various cancer types. The company received $0.9 million in non-dilutive funding through New Jersey's Tax Certificate Transfer Program.
Lisata Therapeutics (LSTA), a clinical-stage pharmaceutical company focused on advanced solid tumor treatments, has scheduled its full year 2024 financial results announcement for Thursday, February 27, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern time to discuss the results and provide a business update.
Participants must pre-register for the conference call through a provided link. Registered attendees will receive dial-in details via email. To ensure smooth participation, attendees are encouraged to dial in 15 minutes before the scheduled start time. A live webcast will be available on Lisata's website under the Investors & News section, with a replay accessible for 12 months after the call.
Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, has announced its participation in the upcoming 2025 BIO CEO & Investor Conference.
The company's President and CEO, David J. Mazzo, PhD, will deliver a corporate overview presentation on Monday, February 10th at 2:00 p.m. Eastern Time. The conference is scheduled to take place from February 10-11, 2025, at the New York Marriott Marquis in New York City.
Lisata Therapeutics (NASDAQ: LSTA) and WARPNINE announced encouraging preliminary results from their Phase 1b/2a iLSTA trial evaluating certepetide in combination with standard-of-care (SoC) chemotherapy and immunotherapy for locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC).
The trial, conducted at St John of God Subiaco Hospital, involved 30 patients in three cohorts. Key preliminary results from 17 patients showed:
- 9 of 16 patients achieved partial response after 4 treatment cycles
- 1 patient exhibited complete response
- 14 of 17 patients showed decreased CA19-9 levels, with 6 patients showing >90% reduction
- All 5 analyzed patients showed significant immune cell infiltration (15% to 50%)
The data suggests certepetide's potential to enhance the effectiveness of various cancer treatments when combined with SoC chemotherapy and immunotherapy.
Lisata Therapeutics (NASDAQ: LSTA) announced preliminary Cohort A data from its Phase 2 ASCEND trial evaluating certepetide with standard chemotherapy in metastatic pancreatic ductal adenocarcinoma. The trial, conducted across 25 sites in Australia and New Zealand, showed encouraging results with a median overall survival of 12.68 months in the certepetide group versus 9.72 months in the placebo group.
The study reported 4 complete responses (6.2%) in the certepetide treatment group compared to none in the placebo group. While the 6-month progression-free survival showed a numerical trend favoring certepetide, both groups had a median PFS of 5.5 months. The trial includes two cohorts: Cohort A with 95 patients receiving a single dose, and Cohort B with 63 patients receiving two doses of certepetide. Data from Cohort B is expected in the coming months, with plans to advance to Phase 3 in early 2026.
Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, has announced its participation in the upcoming 2025 Sequire Investor Summit in San Juan, Puerto Rico.
The company's President and CEO, David J. Mazzo, PhD, will deliver a corporate overview presentation on Wednesday, January 22, 2025, at 10:00 a.m. Atlantic Standard Time. The summit is scheduled to take place from January 21-23, 2025.
Lisata Therapeutics (LSTA) announced completion of patient enrollment in all three cohorts of the Phase 1b/2a CENDIFOX trial, evaluating certepetide in combination with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers. The investigator-initiated trial, led by Dr. Anup Kasi at The University of Kansas Cancer Center, enrolled 66 total patients across three cohorts: 35 with resectable/borderline resectable pancreatic cancer, 18 with high-grade colon and appendiceal cancer with peritoneal metastasis, and 13 with colon cancer with oligo-metastatic disease.
The open-label trial aims to assess safety and therapeutic effects of combining certepetide with neoadjuvant FOLFIRINOX regimens. Results are expected in 2025. The study will provide pre- and post-treatment tumor tissue data for immune profiling and long-term patient outcomes information.
Lisata Therapeutics (NASDAQ: LSTA) and Kuva Labs have announced a global collaboration and license agreement. Kuva gains access to Lisata's certepetide targeting agent to be used with their NanoMark™ MR imaging platform for cancer diagnostics. The partnership aims to create advanced magnetic resonance imaging agents for non-invasive solid tumor detection. Kuva will manage all development and commercialization costs, while Lisata will supply certepetide. The agreement includes an upfront license fee, potential milestone payments, and royalties on future sales for Lisata.